Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.00 -0.26 (-0.49%)
Streaming Delayed Price Updated: 2:15 PM EDT, Oct 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,287,043
Open 53.18
Bid (Size) 52.99 (2)
Ask (Size) 53.01 (10)
Prev. Close 53.26
Today's Range 52.95 - 53.41
52wk Range 42.64 - 58.97
Shares Outstanding 1,250,690,553
Dividend Yield 3.59%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Sanofi and private equity firm CD&R are in negotiations to sell a 50% stake in Opella, Sanofi's consumer healthcare division. With a €16B valuation, Opella is the third-largest player in the global OTC... 
Via Benzinga
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?
Let's look beyond this piece of bad news from regulators. 
Via The Motley Fool

Performance

YTD
+6.00%
+6.00%
1 Month
-7.71%
-7.71%
3 Month
+5.10%
+5.10%
6 Month
+11.13%
+11.13%
1 Year
+1.79%
+1.79%

More News

Read More
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
Via Benzinga
France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block
Via Benzinga
Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R
Via Benzinga
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
Via Chartmill
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Via Benzinga
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
Via Benzinga
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Via Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Via Benzinga
Exposures Product Safety
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Via Benzinga
Topics Economy
Exposures Interest Rates
Week In Review: Zenas Raises $259 Million In IPO
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
Via Benzinga
Exposures Product Safety
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Via Investor's Business Daily
Exposures Product Safety
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Via Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Via Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Via Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Via MarketBeat
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Via Benzinga
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.